Related Experiment Video
Updated: May 9, 2026

Sample Preparation to Bioinformatics Analysis of DNA Methylation: Association Strategy for Obesity and Related Trait Studies
Published on: May 6, 2022
PPARγ and PPARGC1B polymorphisms modify the association between phthalate metabolites and breast cancer risk
Gabriela A Martínez-Nava1, Ana I Burguete-García, Lizbeth López-Carrillo
1National Institute of Public Health , Cuernavaca, Morelos , Mexico and.
Context:
Breast cancer (BC) risk has been differentially associated with urinary levels of some phthalate metabolites.
Objective:
To investigate whether PPARγ and PPARGC1B polymorphisms modulate these associations.
Materials And Methods:
208 BC cases were age-matched with 220 population controls. Phthalate metabolites were determined by HPLC-MS. PPARγ Pro12Ala (rs1801281) and PPARGC1B Ala203Pro (rs7732671) and Val279Ile (rs17572019) were genotyped.
Results:
The association between mono-(2-ethyl-5-hydroxyhexyl) phthalate (MEHHP) and BC risk was positively modified in PPARγ Pro12Ala C carriers. The association with mono-iso-butyl phthalate (MiBP) in PPARGC1B Ala203Pro G carriers was negatively modified.
Conclusion:
PPARγ and PPARGC1B polymorphisms modulate the association between phthalate exposure and BC risk.
Related Concept Videos
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Pharmacogenetics of Drug Metabolism: Overview
Pharmacogenomics: Identification of New Drug Targets
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
Principles of Pharmacogenetics: Types of Genetic Variants
